Nephros (OTCMKTS:NEPH) Receives Buy Rating from Maxim Group

Maxim Group reiterated their buy rating on shares of Nephros (OTCMKTS:NEPH) in a research note released on Thursday, AnalystRatings.com reports. The brokerage currently has a $16.00 target price on the stock.

Several other equities research analysts also recently weighed in on the company. Benchmark assumed coverage on Nephros in a report on Thursday, October 24th. They issued a buy rating and a $16.00 price objective for the company. Zacks Investment Research raised Nephros from a hold rating to a buy rating and set a $12.00 price objective for the company in a report on Friday, October 18th.

NEPH traded up $0.97 on Thursday, reaching $9.00. The company’s stock had a trading volume of 23,603 shares, compared to its average volume of 7,750. The stock has a 50 day moving average of $9.11 and a two-hundred day moving average of $4.79. The company has a quick ratio of 1.86, a current ratio of 2.56 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $61.61 million, a price-to-earnings ratio of -16.67 and a beta of 0.85. Nephros has a fifty-two week low of $3.69 and a fifty-two week high of $11.35.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Nephros (OTCMKTS:NEPH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $3.12 million. Nephros had a negative return on equity of 56.37% and a negative net margin of 49.93%. As a group, analysts anticipate that Nephros will post -0.63 earnings per share for the current fiscal year.

Nephros Company Profile

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Featured Story: Outstanding Shares

Leave a Reply

Your email address will not be published. Required fields are marked *

*